share_log

国信证券4月8日发布研报称，给予荣昌生物（688331.SH）增持评级。评级理由主要包括：1）核心产品商业化推进良好；2）泰它西普多项适应症在中美两地推进临床；3）维迪西妥单抗适应症向前线治疗拓展。（每日经济新闻）

Guoxin Securities released a research report on April 8 stating that it gave Rongchang Biotech (688331.SH) an increase in its holdings. The main reasons for the rating include: 1) commercialization of core products is progressing well; 2) clinical promoti

Zhitong Finance ·  Apr 8 08:26
Guoxin Securities released a research report on April 8 stating that it gave Rongchang Biotech (688331.SH) an increase in its holdings. The main reasons for the rating include: 1) commercialization of core products is progressing well; 2) clinical promotion of multiple indications of tetracipid in China and the US; 3) expansion of verdicitumab indications to front-line treatment. (Mainichi Keizai Shimbun)

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment